Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : APX-115
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aptabio To Initiate Phase II Oral Covid-19 Therapy Trial
Details : Aptabio's APX-115 hinders NOX2 and ROS in the endosome, obstructing the virus pathway. A transmembrane enzyme NADPH oxidase (NOX) inhibitor, APX-115 was studied in Europe for treating patients with diabetes complications.
Brand Name : APX-115
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 25, 2021
Lead Product(s) : APX-115
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?